REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion
14,70 EUR
±0,00 %±0,00
19. May, 17:52:38 Uhr,
Lang & Schwarz
Kommentare 84
Summer.76,
11.04.2023 15:10 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-receives-fda-fast-track-designation-for-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy-301794029.html
Summer.76,
03.05.2023 22:10 Uhr
0
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-reports-first-quarter-2023-financial-results-and
Summer.76,
02.08.2023 22:07 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2023-financial-results-and-recent-operational-highlights-301891935.html
Summer.76,
04.10.2023 5:15 Uhr
0
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
https://www.prnewswire.com/news-releases/regenxbio-presents-interim-clinical-data-from-phase-iii-affinity-duchenne-trial-of-rgx-202-at-28th-annual-international-congress-of-the-world-muscle-society-301946289.html
Summer.76,
07.02.2024 19:01 Uhr
0
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-completion-enrollment-cohort-2-and
Summer.76,
28.02.2023 22:07 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-2022-and-full-year-2022-financial-results-and-recent-operational-highlights-301758593.html
Summer.76,
22.02.2023 22:41 Uhr
0
https://www.prnewswire.com/news-releases/additional-positive-interim-data-from-phase-iiiiii-campsiite-trial-of-regenxbios-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-presented-at-19th-annual-worldsymposiumtm-301753564.html
Summer.76,
11.02.2023 22:48 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-presents-interim-data-from-phase-ii-bridging-study-evaluating-the-clinical-performance-of-rgx-314-using-the-navxpress-manufacturing-platform-process-301744570.html
Summer.76,
23.01.2023 16:56 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-announces-phase-iii-trial-of-rgx-202-a-novel-gene-therapy-candidate-for-duchenne-muscular-dystrophy-is-active-and-recruiting-patients-301727802.html
Summer.76,
21.12.2022 13:11 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-reports-update-on-advancement-of-programs-for-cln2-disease-301707881.html
Summer.76,
08.12.2022 21:18 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-announces-completion-of-dosing-in-the-phase-iii-trial-of-rgx-111-for-the-treatment-of-severe-mps-i-301697997.html
Summer.76,
03.11.2022 17:22 Uhr
0
https://finance.yahoo.com/news/regenxbio-rgnx-reports-q3-loss-124512911.html
Summer.76,
03.11.2022 12:41 Uhr
0
https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2022-financial-results-and-recent-operational-highlights-301667151.html
Summer.76,
03.10.2022 19:51 Uhr
0
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
https://www.prnewswire.com/news-releases/regenxbio-announces-additional-positive-interim-data-from-trials-of-rgx-314-for-the-treatment-of-wet-amd-301638557.html
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | ARTEC Hauptdiskussion | ±0,00 % | |
2 | Jaguar Health für Investierte und Interessierte | ±0,00 % | |
3 | GAMESTOP Hauptdiskussion | +0,59 % | |
4 | DAX Hauptdiskussion | +0,13 % | |
5 | Mainz Biomed | ±0,00 % | |
6 | Dax Prognose | +0,13 % | |
7 | REALTY INCOME Hauptdiskussion | ±0,00 % | |
8 | Nio für normale Kommunikation | ±0,00 % | |
9 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
10 | Polestar Automotive | ±0,00 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | ARTEC Hauptdiskussion | ±0,00 % | |
2 | Jaguar Health für Investierte und Interessierte | ±0,00 % | |
3 | GAMESTOP Hauptdiskussion | +0,59 % | |
4 | Mainz Biomed | ±0,00 % | |
5 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
6 | Nio für normale Kommunikation | ±0,00 % | |
7 | Polestar Automotive | ±0,00 % | |
8 | Canopy Hauptforum | ±0,00 % | |
9 | REALTY INCOME Hauptdiskussion | ±0,00 % | |
10 | HYMC | -1,38 % | Alle Diskussionen |